Also found in: Dictionary, Thesaurus.
Related to Ganymed: Ganymede


(religion, spiritualism, and occult)

Ganymed is asteroid 1,036 (the 1,036th asteroid to be discovered, on October 23, 1924). It is approximately 40 kilometers in diameter and has an orbital period of 4.3 years. It was named after the youth who was kidnapped to become the cupbearer of Zeus. Jacob Schwartz gives the astrological significance of this asteroid as “beautiful and attractive to both genders, the mortal becoming divine by surrendering to the divine.” According to J. Lee Lehman, “the asteroid Ganymed shows how we are able to submit ourselves to that which is beyond our personal power. In negative form, it is the way we evade even the awareness that there is anything beyond our own powers.”


Kowal, Charles T. Asteroids: Their Nature and Utilization. Chichester, West Sussex, UK: Ellis Horwood Limited, 1988.
Lehman, J. Lee. The Ultimate Asteroid Book. West Chester, PA: Whitford Press, 1988.
Schwartz, Jacob. Asteroid Name Encyclopedia. St. Paul, MN: Llewellyn Publications, 1995.
References in periodicals archive ?
Under the agreement, Astellas acquired 100% of the equity in Ganymed, and in addition, Ganymed's shareholders were eligible to receive up to USD 940.
The acquisition of Ganymed will enable Astellas to further expand our oncology presence by adding a late-stage antibody asset with the potential to establish a new pillar following XTANDI," commented Yoshihiko Hatanaka, President and CEO, Astellas.
Ozlem Tureci, chief executive officer and co-founder of Ganymed said, "I am impressed by the competence, commitment and vision of Astellas.
Upon completion of the transaction, which is expected in the coming weeks, Ganymed will become a wholly owned subsidiary of the Japanese firm.
With completion of the transaction, Ganymed became a wholly owned subsidiary of Astellas.
Pharmaceutical company Astellas Pharma Inc (TSE: 4503) and Ganymed Pharmaceuticals AG, a German biopharmaceutical company that focuses on the development of antibodies against cancer, announced on Friday that the shareholders of both companies have agreed the acquisition of Ganymed by Astellas.
Global Markets Direct's, 'Ganymed Pharmaceuticals AG - Product Pipeline Review - 2014', provides an overview of the Ganymed Pharmaceuticals AG's pharmaceutical research and development focus.
23 October 2013 - German anticancer drugs developer Ganymed Pharmaceuticals AG said earlier this week that its monoclonal antibody, IMAB362, had received orphan drug status from the US FDA and the European Medicines Agency (EMA) as a therapy of pancreatic cancer.
Bionucleon Srl, GANYMED Pharmaceuticals AG, Ora Bio Ltd.
87m to (EUR 422m) acquire Mainz, Germany-based biopharmaceutical company Ganymed Pharmaceuticals AG, the company said.
M2 EQUITYBITES-October 31, 2016-Japan's Astellas to Acquire German Drugmaker Ganymed for EUR 422m